Recursion Pharmaceuticals (RXRX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
RXRX jumps 11.2% to $4.16 on 3.0x normal volume. Closed at $4.16, +11.23% vs the prior close of $3.74. Day range $3.53–$4.41, opened at $3.65.
RXRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RXRX jumps 11.2% to $4.16 on 3.0x normal volume
- Closed at $4.16, +11.23% vs the prior close of $3.74. Day range $3.53–$4.41, opened at $3.65.
- Volume was 62.78M shares, 3.0x its 50-day average of 21.21M — unusually heavy trading.
- Price is +14.9% vs its 50-day average ($3.62) and +16.7% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 32% of that range, 42.1% below the 52-week high.
- SEC filings that day: 424B5, 8-K, 424B5.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 14, 2026 — RXRX dips 2.5% to $3.74, 3 down days in a row
- Closed at $3.74, -2.48% vs the prior close of $3.84. Day range $3.66–$3.91, opened at $3.72.
- Volume was 18.78M shares, 0.9x its 50-day average of 21.26M.
- Price is +3.9% vs its 50-day average ($3.60) and +4.9% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 22% of that range, 47.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — RXRX slides 4.4% to $3.84
- Closed at $3.84, -4.36% vs the prior close of $4.01. Day range $3.82–$4.05, opened at $4.01.
- Volume was 19.76M shares, 0.9x its 50-day average of 21.16M.
- Price is +6.8% vs its 50-day average ($3.59) and +7.5% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 24% of that range, 46.6% below the 52-week high.
Oct 12, 2026 — RXRX slides 8.0% to $4.01
- Closed at $4.01, -8.03% vs the prior close of $4.36. Day range $3.91–$4.36, opened at $4.31.
- Volume was 23.79M shares, 1.1x its 50-day average of 20.99M.
- Price is +12.1% vs its 50-day average ($3.58) and +12.3% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 28% of that range, 44.2% below the 52-week high.
Oct 9, 2026 — RXRX jumps 10.4% to $4.36
- Closed at $4.36, +10.38% vs the prior close of $3.95. Day range $3.89–$4.43, opened at $4.01.
- Volume was 35.50M shares, 1.7x its 50-day average of 20.49M.
- Price is +22.6% vs its 50-day average ($3.56) and +22.0% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 36% of that range, 39.3% below the 52-week high.
Oct 8, 2026 — RXRX slides 7.5% to $3.95, 3 down days in a row
- Closed at $3.95, -7.49% vs the prior close of $4.27. Day range $3.79–$4.20, opened at $4.19.
- Volume was 30.90M shares, 1.5x its 50-day average of 20.23M.
- Price is +11.9% vs its 50-day average ($3.53) and +10.6% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 27% of that range, 45.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — RXRX slides 7.8% to $4.27 on 2.0x normal volume
- Closed at $4.27, -7.78% vs the prior close of $4.63. Day range $4.23–$4.60, opened at $4.51.
- Volume was 40.73M shares, 2.0x its 50-day average of 19.90M — unusually heavy trading.
- Price is +21.6% vs its 50-day average ($3.51) and +19.5% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 34% of that range, 40.5% below the 52-week high.
Oct 6, 2026 — RXRX slides 3.1% to $4.63 on 3.8x normal volume
- Closed at $4.63, -3.14% vs the prior close of $4.78. Day range $4.39–$5.19, opened at $4.81.
- Volume was 71.11M shares, 3.8x its 50-day average of 18.92M — unusually heavy trading.
- Price is +32.8% vs its 50-day average ($3.49) and +29.5% vs its 200-day average ($3.58).
- 52-week range $2.77–$7.18; today's close sits at 42% of that range, 35.5% below the 52-week high.
Oct 5, 2026 — RXRX jumps 16.0% to $4.78, a 6-month high on 3.8x normal volume
- Closed at $4.78, +16.02% vs the prior close of $4.12. Day range $4.06–$4.93, opened at $4.16.
- Volume was 67.28M shares, 3.8x its 50-day average of 17.90M — unusually heavy trading.
- Price is +38.4% vs its 50-day average ($3.45) and +33.7% vs its 200-day average ($3.58).
- 52-week range $2.77–$7.18; today's close sits at 46% of that range, 33.4% below the 52-week high.
Oct 2, 2026 — RXRX rises 1.2% to $4.12
- Closed at $4.12, +1.23% vs the prior close of $4.07. Day range $4.01–$4.27, opened at $4.18.
- Volume was 18.84M shares, 1.1x its 50-day average of 17.90M.
- Price is +20.5% vs its 50-day average ($3.42) and +15.3% vs its 200-day average ($3.57).
- 52-week range $2.77–$7.18; today's close sits at 31% of that range, 42.6% below the 52-week high.
RXRX latest news & SEC filings
Every SEC filing by or about RXRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Oct 15, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 7, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Borgeson Blake sold 50,000 shares at $4.84 (≈$242.00K) on Oct 6, 2026; now holds 6,108,287
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hershberg Robert converted options/RSUs into 25,000 shares at $2.22 (≈$55.50K) on Oct 6, 2026; now holds 187,156
- Hershberg Robert sold 25,000 shares at $5.00 (≈$125.00K) on Oct 6, 2026; now holds 162,156
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dar Zavain received an award of 4,607 shares on Oct 1, 2026; now holds 245,371
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Li Dean Y received an award of 3,378 shares on Oct 1, 2026; now holds 1,476,707
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 7, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $7.67M (prior year $19.22M) (-60.1% vs Jun 30, 2025)
- Net income: -$131.00M (prior year -$171.90M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.25 (prior year -$0.41) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RXRX
- Last results release: Oct 15, 2026 (8-K Item 2.02). Previous ones: Aug 5, 2026, May 6, 2026, Feb 25, 2026. Based on that rhythm, the next report is likely around Jan 14, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.88% (largest 16.0%). That is a volatile stock.
- Liquidity: about 32.52M shares (≈$135.28M) trade per day on average.
- 52-week position: $4.16 vs a range of $2.77–$7.18 (32% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Najat Khan sold 22,408 shares on Sep 8, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Sep 21, 2026; 10-Q Aug 5, 2026.
- Share count: 535.34M shares outstanding (Jul 31, 2026), +218.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
RXRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 3.65 | 4.41 | 3.53 | 4.16 | 62.78M |
| Oct 14, 2026 | 3.72 | 3.91 | 3.66 | 3.74 | 18.78M |
| Oct 13, 2026 | 4.01 | 4.05 | 3.82 | 3.84 | 19.76M |
| Oct 12, 2026 | 4.31 | 4.36 | 3.91 | 4.01 | 23.79M |
| Oct 9, 2026 | 4.01 | 4.43 | 3.89 | 4.36 | 35.50M |
| Oct 8, 2026 | 4.19 | 4.20 | 3.79 | 3.95 | 30.90M |
| Oct 7, 2026 | 4.51 | 4.60 | 4.23 | 4.27 | 40.73M |
| Oct 6, 2026 | 4.81 | 5.19 | 4.39 | 4.63 | 71.11M |
| Oct 5, 2026 | 4.16 | 4.93 | 4.06 | 4.78 | 67.28M |
| Oct 2, 2026 | 4.18 | 4.27 | 4.01 | 4.12 | 18.84M |
| Oct 1, 2026 | 4.07 | 4.17 | 3.96 | 4.07 | 17.48M |
| Sep 30, 2026 | 4.09 | 4.29 | 3.98 | 4.13 | 32.79M |
| Sep 29, 2026 | 3.73 | 4.04 | 3.72 | 4.03 | 21.56M |
| Sep 28, 2026 | 3.69 | 3.84 | 3.66 | 3.70 | 13.06M |
| Sep 25, 2026 | 3.89 | 3.90 | 3.70 | 3.74 | 10.48M |
| Sep 24, 2026 | 3.65 | 3.90 | 3.61 | 3.89 | 19.34M |
| Sep 23, 2026 | 4.03 | 4.09 | 3.66 | 3.70 | 23.67M |
| Sep 22, 2026 | 4.00 | 4.16 | 3.90 | 4.05 | 40.46M |
| Sep 21, 2026 | 3.92 | 4.01 | 3.83 | 3.97 | 37.73M |
| Sep 18, 2026 | 3.54 | 3.83 | 3.50 | 3.83 | 44.33M |
About Recursion Pharmaceuticals
Recursion Pharmaceuticals (RXRX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SALT LAKE CITY, UT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1601830.
RXRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Blake Borgeson | Director | Sep 2, 2026 |
| Namandje Bumpus | Director | Jun 22, 2026 |
| Zavain Dar | Director | Jul 2, 2026 |
| Christopher Gibson | Director | Jun 5, 2026 |
| Robert Hershberg | Director | Jun 22, 2026 |
| Najat Khan | CEO and President | Sep 10, 2026 |
| Dean Y Li | Director | Jul 2, 2026 |
| Franziska Michor | Director | Jun 22, 2026 |
| Elaine D Sun | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Hallett | Chief Scientific Officer | Aug 18, 2026 |
| Najat Khan | CEO and President | Sep 10, 2026 |
| Ben R Taylor | Chief Financial Officer | Sep 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Najat Khan | Sale | 22,408 | $3.52 |
| Sep 1, 2026 | Blake Borgeson | Sale | 30,000 | $3.34 |
| Aug 4, 2026 | Blake Borgeson | Sale | 30,000 | $3.25 |
| Jul 7, 2026 | Blake Borgeson | Sale | 40,000 | $3.96 |
| Jun 18, 2026 | Namandje Bumpus | Sale | 3,963 | $3.18 |
| Jun 5, 2026 | Christopher Gibson | Sale | 40,000 | $3.62 |
| Jun 5, 2026 | Najat Khan | Sale | 23,588 | $3.58 |
| Jun 3, 2026 | Namandje Bumpus | Sale | 4,386 | $3.54 |
| Jun 2, 2026 | Blake Borgeson | Sale | 30,000 | $3.68 |
| May 22, 2026 | Christopher Gibson | Sale | 40,000 | $3.08 |
| May 7, 2026 | Christopher Gibson | Sale | 40,000 | $3.37 |
| May 5, 2026 | Blake Borgeson | Sale | 30,000 | $3.52 |
| Apr 22, 2026 | Christopher Gibson | Sale | 40,000 | $3.61 |
| Apr 7, 2026 | Christopher Gibson | Sale | 40,000 | $3.10 |
| Apr 7, 2026 | Blake Borgeson | Sale | 30,000 | $3.10 |
RXRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $74.68M | $-644.76M | -1.44 | $-371.81M |
| Dec 31, 2024 | $58.84M | $-463.66M | -1.69 | $-359.17M |
| Dec 31, 2023 | $44.58M | $-328.07M | -1.58 | $-287.78M |
| Dec 31, 2022 | $39.84M | $-239.48M | -1.36 | $-83.52M |
| Dec 31, 2021 | $10.18M | $-186.48M | -1.49 | $-158.61M |
Latest balance sheet: total assets $1.21B, total liabilities $297.67M, cash $545.68M (as of Jun 30, 2026).
RXRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 15, 2026 | 8-K Item 2.02 (results) | $4.16 |
| Aug 5, 2026 | 8-K Item 2.02 (results) | $3.17 |
| May 6, 2026 | 8-K Item 2.02 (results) | $3.43 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $3.77 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $4.96 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $5.53 |
| May 5, 2025 | 8-K Item 2.02 (results) | $4.76 |
| Feb 28, 2025 | 8-K Item 2.02 (results) | $7.51 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $6.97 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)ImmunityBio (IBRX)Repligen (RGEN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RXRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.